NCT06055738

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

An Exploratory Clinical Study of Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Tang-Du Hospital · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single arm, phase II clinical study to evaluate the efficacy and safety of Zimberelimab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer.

Detailed description

This study will enroll patients with IB3 and IIA2 locally advanced cervical cancer who received three cycles of neoadjuvant Zimberelimab combined with albumin-bound paclitaxel and cisplatin to evaluate the efficacy and safety.

Conditions

• Locally Advanced Cervical Cancer

Interventions

Type	Name	Description
DRUG	Zimberelimab	240mg,d1,iv,Q21D
DRUG	Albumin-bound Paclitaxel	260mg/m2,d1,iv,Q21D
DRUG	Cisplatin	75mg/m2,d1,iv,Q21D

Timeline

• Start date: 2023-10-09
• Primary completion: 2026-12-30
• Completion: 2027-12-30
• First posted: 2023-09-28
• Last updated: 2023-09-28

Locations

1 site across 1 country: China